Kumar Danish, Taha Yaseen Raja, Panezai Muhammad Qaiser, Naeem Muhammad Usman, Ismail Hina, Majid Zain, Mehmood Nasir, Ali Khalid Muhammad, Lail Ghulamullah, Hassan Luck Nasir
Department of Hepatogastroenterology, Sindh Institute of Urology and Transplantation, Karachi, PAK.
Department of Gastroenterology, Sheik Zayed Hospital, Lahore, PAK.
Cureus. 2024 Jan 30;16(1):e53243. doi: 10.7759/cureus.53243. eCollection 2024 Jan.
Introduction Limited studies are available for predicting mortality in patients with spontaneous bacterial peritonitis (SBP) based on ascitic fluid analysis. Recently, a proposition has been made regarding the role of ascitic fluid lactate as a better prognostic indicator of mortality in cirrhotic patients with SBP. Therefore, we aimed to evaluate the utility of ascitic fluid lactate in predicting mortality in cirrhotic patients with SBP. Methods This was a prospective, observational study that was conducted in the Hepato-Gastroenterology Department of Sindh Institute of Urology and Transplantation (SIUT), Karachi from 1 January 2022 to 31 December 2022. All the patients having liver cirrhosis with ascites, aged between 18 and 65 years, and presenting with fever and/or abdominal pain were recruited in the study in the first six months (i.e., from 1 January 2022 to 30 June 2022) and were followed for six more months for the outcome. However, those patients on dialysis or those with hepatocellular carcinoma, any other malignancy as per a history of solid organ transplant, a history of HIV infection, or those underlying systemic sepsis or infections other than SBP were excluded from the study. The presence or absence of SBP was confirmed by doing the ascitic fluid analysis. Ascitic fluid lactate levels were also requested in each patient. Mortality was assessed at one, two, three, and six months, respectively. All the data were analyzed using SPSS version 23.0. The area under the receiver operating curve (AUROC) was obtained for ascitic fluid lactate for predicting mortality in SBP. At an optimal cutoff, the diagnostic accuracy of ascitic fluid lactate was obtained. Results The total number of cirrhotic patients included in the study was 123. The majority of the patients belong to Child Turcotte Pugh (CTP) class C (n = 88; 71%). Two third of the patients (65.8%; n = 81) had viral hepatitis i.e., hepatitis B, D, and/or C, as the cause of cirrhosis. Overall mortality was observed in 51(41.5%) patients. Ascitic fluid lactate was significantly raised in patients with SBP than in patients with non-SBP (p = 0.004). The AUROC of ascitic fluid lactate was highest at three months (AUROC = 0.88) followed by six months (AUROC = 0.84), two months (AUROC = 0.804), and one month (AUROC=0.773). At an optimal cut-off of more than or equal to 22.4 mg/dl, ascitic fluid lactate had a sensitivity of 84.9%, specificity of 85.7%, positive predictive value (PPV) of 97.3%, negative predictive value of 42.8% with diagnostic accuracy of 85% in predicting overall mortality in patients with SBP. On sub-analysis, the diagnostic accuracy of ascitic fluid lactate was highest at six months followed by at three, two, and one month, respectively. Conclusion Ascitic fluid lactate showed a good diagnostic utility in predicting the overall mortality in patients with SBP with the best diagnostic accuracy in predicting long-term (six months) mortality. However, further studies are required to validate our results.
基于腹水分析预测自发性细菌性腹膜炎(SBP)患者死亡率的研究有限。最近,有人提出腹水乳酸在预测肝硬化合并SBP患者死亡率方面可能是一个更好的预后指标。因此,我们旨在评估腹水乳酸在预测肝硬化合并SBP患者死亡率中的作用。
这是一项前瞻性观察性研究,于2022年1月1日至2022年12月31日在卡拉奇信德泌尿与移植研究所(SIUT)的胃肠肝病科进行。在最初六个月(即2022年1月1日至2022年6月30日)招募了所有年龄在18至65岁之间、患有肝硬化腹水且伴有发热和/或腹痛的患者,并对其随访六个月以观察结局。然而,接受透析的患者、患有肝细胞癌的患者、有实体器官移植史的其他任何恶性肿瘤患者、有HIV感染史的患者,或患有除SBP以外的全身性败血症或感染的患者被排除在研究之外。通过腹水分析确认是否存在SBP。还要求检测每位患者的腹水乳酸水平。分别在1个月、2个月、3个月和6个月时评估死亡率。所有数据使用SPSS 23.0版进行分析。获得腹水乳酸预测SBP患者死亡率的受试者工作特征曲线下面积(AUROC)。在最佳临界值时,获得腹水乳酸的诊断准确性。
纳入研究的肝硬化患者总数为123例。大多数患者属于Child Turcotte Pugh(CTP)C级(n = 88;71%)。三分之二的患者(65.8%;n = 81)因病毒性肝炎(即乙型、丁型和/或丙型肝炎)导致肝硬化。观察到51例(41.5%)患者总体死亡。SBP患者的腹水乳酸水平显著高于非SBP患者(p = 0.004)。腹水乳酸的AUROC在3个月时最高(AUROC = 0.88),其次是6个月(AUROC = 0.84)、2个月(AUROC = 0.804)和1个月(AUROC = 0.773)。在最佳临界值为大于或等于22.4 mg/dl时,腹水乳酸预测SBP患者总体死亡率的敏感性为84.9%,特异性为85.7%,阳性预测值(PPV)为97.3%,阴性预测值为42.8%,诊断准确性为85%。亚组分析显示,腹水乳酸的诊断准确性在6个月时最高,其次分别是3个月、2个月和1个月。
腹水乳酸在预测SBP患者总体死亡率方面显示出良好的诊断效用,在预测长期(6个月)死亡率方面诊断准确性最佳。然而,需要进一步研究来验证我们的结果。